JGC
IMMX icon

J. Goldman & Co’s Immix Biopharma IMMX Stock Holding History

J. Goldman & Co’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.08M Buy
228,089
+109,828
+93% +$807K 0.06% 312
2025
Q4 		$619K Buy
+118,261
New +$487K 0.02% 440

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

J. Goldman & Co's IMMX Position: Q1 2026 in Review

J. Goldman & Co increased its Immix Biopharma (IMMX) stake by 93% in Q1 2026, buying an estimated $807K and bringing the position to 228,089 shares worth $2.08M. The position accounts for 0.06% of the portfolio, ranked #312.

J. Goldman & Co first reported a position in IMMX in Q4 2025 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • J. Goldman & Co held 228,089 shares of Immix Biopharma worth $2.08M as of Q1 2026.
  • J. Goldman & Co bought 109,828 Immix Biopharma shares in Q1 2026, an estimated $807K.
  • Immix Biopharma made up 0.06% of J. Goldman & Co's portfolio in Q1 2026, its #312 holding.
  • J. Goldman & Co first reported a position in Immix Biopharma in Q4 2025 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.